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Abstract
The present study examines the postnatal reproductive development of male rats following
prenatal exposure to an atrazine metabolite mixture (AMM) consisting of the herbicide atrazine
and its environmental metabolites diaminochlorotriazine, hydroxyatrazine, deethylatrazine, and
deisopropylatrazine. Pregnant Long Evans rats were treated by gavage with 0.09, 0.87, or 8.73 mg
AMM/kg body weight (BW), vehicle, or 100 mg ATR/kg BW positive control, on gestation days
15-19. Preputial separation was significantly delayed in 0.87 mg and 8.73 mg AMM-exposed
males. AMM-exposed males demonstrated a significant treatment-related increase in incidence
and severity of inflammation in the prostate on postnatal day (PND) 120. A dose-dependent
increase in epididymal fat masses and prostate foci were grossly visible in AMM-exposed
offspring. These results indicate that a short, late prenatal exposure to mixture of chlorotriazine
metabolites can cause chronic prostatitis in male LE rats. The mode of action for these effects is
presently unclear.
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Atrazine (ATR; 2-chloro-N-ethyl-N′-isopropyl-[1,3,5] triazine), a chloro-s- triazine, is one
of the most widely applied herbicides in the United States for control of broadleaf weeds and
grasses in crops of corn, sugar cane, and sorghum [1]. Plants, animals, and microbes each
catabolize chlorotriazines and resulting metabolites are relatively persistent in the
environment, with half-lives exceeding one year in soil and nearly twice as long in water [2].
Because of its environmental persistence and potential to enter drinking water supplies, ATR
has been banned in the European Union [3].
Although the precise mechanism of action remains to be elucidated at certain tissue sites,
studies have demonstrated that ATR adversely affects the endocrine system and
reproductive tissues in the rat (reviewed in [4,5]). In female rats, ATR has been shown to
interfere with a number of endocrine processes through disruption of pituitary-ovarian
function via the hypothalamus [6]. For instance, delayed pubertal development [7],
prolonged estrous cycling and delayed ovulation [8-10] following ATR exposure have been
attributed to suppression of the ovulatory luteinizing hormone (LH) surge by ATR. Female
Long-Evans (LE) offspring of untreated dams cross-fostered to dams gavage dosed with
ATR in pregnancy exhibited delayed puberty and mammary gland development associated
with significantly lower proliferation-associated markers, specifically, mammary gland-
specific aromatase and epidermal growth factor receptor gene expression [11].
Exposure to ATR has also been shown to affect reproductive tissues in male rats. Stoker et
al. [12] observed increased myeloperoxidase activity in the lateral prostate (LP) of male
offspring of Wistar rats following early lactational exposure to ATR. This inflammatory
effect was attributed to inhibition of the suckling-induced prolactin (PRL) release that is
involved in regulating the maturation of the dopaminergic neurons shortly before and after
birth [12]. Puberty was delayed in male Wistar rats exposed to ATR peripubertally and those
rats in the highest dose group exhibited decreased testicular testosterone [13]. In another
study [14], male LE rats exposed in utero to 100 mg ATR/kg BW exhibited delayed
attainment of puberty and increased LP weights at necropsy on PND120 and PND220, as
well as visible signs of prostatic inflammation.
Animal catabolism of ATR and other chlorotriazines, including simazine and propazine,
occurs by dealkylation, dechlorination, and conjugation (Figure 1). The parent
chlorotriazines produce the same set of four metabolites that have been detected in animals,
soil/sediment, and surface and ground waters; hydroxyatrazine (HA; 6-hydroxy-N-ethyl-N′-
isopropyl-[1,3,5] triazine-2,4-diamine), diaminochlorotriazine (DACT; 6-chloro-[1,3,5]
triazine-2,4-diamine), deisopropylatrazine (DIA; 6-chloro-N-ethyl-[1,3,5] triazine-2,4-
diamine), and deethylatrazine (DEA; 6-chloro-N-isopropyl-[1,3,5] triazine-2,4-diamine).
Although ATR is currently seldom detected at levels exceeding the U.S. Environmental
Protection Agency maximum contaminant level (MCL) of 3 ppb (3 μg/L) in ground water
[15,16], the U.S. Geological Survey National Water-Quality Assessment Watershed
Regressions for Pesticides Atrazine Model [17], recently updated with 2007 ATR
agricultural use data [18], predicts “…streams with a greater than 5-percent probability of
exceeding the benchmark represent about 6 percent of the Nation's stream miles (36,829 of
649,935 mi)” and that “Approximately 546 stream miles (less than 1/10th of 1 percent of the
Nation's stream miles) are predicted to have more than a 50-percent probability of exceeding
3 μg/L.” Moreover, ATR metabolites commonly occur at levels higher that ATR itself
[12,19] and MCLs for the metabolites (individually or cumulatively) have not been
established. In an analysis of 233 early summer pre- and post-emergence run-off event
samples from 76 Midwestern stream or reservoir outflows and 70 low flow samples
collected at 70 Midwestern streams, Battaglin et al. [20] reported that ATR was detected in
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at least 80% of the samples at a median concentration of 4.07 μg/L in pre-emergence sites
and 2.69 μg/L at post-emergence sites. Furthermore, three ATR metabolites, DEA, DIA, and
HA, were detected in at least 50% of the samples with concentrations of DEA (0.41 and 0.54
μg/L) and DIA (0.32 and 0.39 μg/L) being the highest in pre- and post-emergence sites,
respectively, and HA (0.29 μg/L) being the highest in low flow samples [20]. And in another
study, atrazine and up to three of its degradation products were identified at sites in Rock
Creek National Park in Washington D.C., Chesapeake and Ohio Canal National Historic
Park in Maryland, DeSoto National Wildlife Refuge in Missouri Valley, Iowa, and Seminole
State Park near Sinclair, Wyoming [21].
Studies utilizing individual ATR metabolites demonstrated delayed puberty in both male and
female Wistar rats and the investigators concluded that atrazine molar equivalents (AME) of
ATR chlorinated metabolites may be as potent as ATR itself and may also mediate the
effects of ATR [22,23]. Enoch et al. [24] first reported developmental effects in female rats
following prenatal exposure to low doses of a mixture of ATR and its metabolites. The
atrazine metabolite mixture (AMM) was formulated to contain ATR and its metabolites
DACT, HA, DEA, and DIA in AME proportions and at levels reported in a survey of ground
and surface water potentially containing ATR [25-27]. Late prenatal exposure of LE rats to
this AMM, which was also used in the present study, delayed mammary gland development
of female offspring, evident as early as weaning in all treatment groups [24]. Mammary
gland developmental impairments from AMM exposure were as severe as those observed in
offspring prenatally exposed to the positive control group (high dose ATR), and were
present when no significant effects on day of vaginal opening, a female pubertal indicator,
or decreased body weight were observed. These findings suggest that the rat mammary
gland may be particularly sensitive to the effects of atrazine metabolites or that the ATR
metabolites, used together, are particularly potent in mediating the effects on some, but not
all reproductive tissues.
The objective of the current study was to examine the potential for alterations in the
reproductive development of male rat offspring following late prenatal exposure, during the
period of fetal prostate development, to a relatively low concentration mixture of ATR
metabolites as described in Enoch et al. [24]. In recent ATR risk assessment documents
[15,28], the ATR “Short-term” (1-30 days) exposure value was determined using the no
observed adverse effect level (NOAEL), and the lowest observed adverse effect level
(LOAEL) for effects on male pup reproductive tissue as the endpoints of concern. The data
presented here provide information regarding the effects of exposure to a metabolite mixture
administered at doses considerably lower than the current developmental ATR NOAEL of
6.25 mg/kg/day and LOAEL of 12.5 mg/kg/day [15,28].
2. Methods
2.1 Animals
Timed pregnant Long-Evans rats (9-15 wk old, sperm positive = Day 0) were obtained from
Charles River Breeding Laboratories (Raleigh, NC). Females were housed in an Association
for Assessment and Accreditation of Laboratory Animal Care accredited facility in clear
plastic cages containing heat-treated pine shavings (Beta Chips, North Eastern Products Inc.,
Warrensburg, NY) and given food (Purina 5008 Rodent Chow, Ralston Purina Co., St.
Louis, MO) and water ad libitum. Once weaned, the male offspring were housed 3-4/cage
and fed Purina 5001 chow ad libitum. The animals were maintained in a room with a 14:10-
hour light/dark cycle (2100 hr lights out), at 20-24° C, and 40-50% relative humidity. All
animals were treated humanely and with regard for alleviation of potential suffering, as
approved by the U.S. EPA National Health and Environmental Effects Research
Laboratory's Institutional Animal Care and Use Committee.
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ATR and all metabolites (Syngenta Crop Protection, Inc. Greensboro, NC; 94.5-98.2%
purity) were prepared as a suspension in 1.0% methylcellulose (Sigma-Aldrich Chemical
Co., Inc., St. Louis, MO) in distilled water. The AMM consists of ATR (25% by weight),
DACT (35%, 1.482 AME), HA (20%, 1.094 AME), DEA (15%, 1.149 AME) and DIA (5%,
1.242 AME) and was prepared as detailed in Enoch et al. [24]. Dose groups included 0 (1%
methylcellulose vehicle), 0.09, 0.87, 8.73 mg AMM/kg BW/d and 100 mg ATR/kg BW/d,
which were delivered in a volume of 5.0 ml vehicle/kg BW. Solutions were stirred
constantly between dosing periods and were agitated between dosing of individual animals
to maintain as consistent a fine suspension as possible.
2.3 Experimental design
The study was conducted in two replicates (blocks) with five treatment groups per block
(positive and negative controls present in each block) as depicted in Figure 2. Based on
results from these blocks, a third block was conducted to include a 180 day necropsy.
Pregnant Long Evans rats (n ≥ 6/treatment/block) were gavage dosed with 0, 0.09, 0.87 or
8.73 mg AMM/kg BW/d (hereafter referred to as mg AMM) or 100 mg ATR/kg BW/d
(hereafter referred to as mg ATR) on GD15-19. The animals in this study were the siblings
to those in Enoch et al. [24], which focused on the effects of AMM on mammary gland
development. Exposure was conducted on GD15-19 because this dosing window is a critical
period of development for both the mammary gland and prostate [29,30]. Because ATR is
rapidly metabolized in the adult rat, half-doses were administered b.i.d. (0700 and 1400 hr),
adjusted for morning BW, in order to emulate near steady state exposure. Total single day
dose of 0, 0.09, 0.87, or 8.73 mg AMM or 100 mg ATR are reported for consistency with
previous studies. The 100 mg ATR dose was chosen as a positive control to compare
directly with results from previous studies [14]. On PND4, pups were weighed and litters
equalized to six female and four male pups. Animals were weighed on PND4, 21, 120, and
180. Typically, two male pups were randomly selected from each of at least five dams (n ≥
10, specific n provided in legends) for pubertal assessment and necropsy. Necropsy was
conducted on PND120 in blocks one and two and on PND120 and 180 in block three.
Fetal BW was obtained as described in Enoch et al. [24]. In a separate study, timed-pregnant
Long-Evans dams were treated with 0 or 8.73 mg AMM/kg BW (n = 8 dams/treatment) on
GD15–GD19 and euthanized on GD20. Litters were removed from the dam and the sex and
weight of each fetus was recorded. One control dam died during this portion of the study.
2.4 Preputial Separation
The separation of the prepuce from the glans penis, preputial separation (PPS), is a reliable
indicator of puberty in the male rat [31]. In LE rats, PPS generally occurs from 40-42 days
of age. Male rats were examined daily as described in Korenbrot et al. [31], at
approximately the same time of day, beginning on PND38 and continuing until PPS was
achieved in all animals. Age and weight were recorded when full PPS was observed.
2.5 Necropsy and tissue collection
The necropsy from which the prostate tissues were obtained for these studies was conducted
by a contracted team (Experimental Pathology Laboratory, EPL; Research Triangle Park,
NC) that included a board certified veterinary pathologist. All weights and observations
during necropsy were recorded. Animals were isolated in a quiet holding room for at least
12 hours prior to necropsy, which was conducted between 0800 and 1400 hr. At necropsy on
PND120 and PND180, animals were weighed, euthanized by decapitation, and trunk blood
was collected. Serum was separated from the blood by centrifugation at 4°C for 15 min. at
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3500 rpm and stored frozen at −80°C for hormone and cytokine assays. The anterior
pituitary (AP) was removed, weighed, and frozen at −80°C for pituitary prolactin and
thyroid-stimulating hormone assays. Both horns of the seminal vesicle (SV) were removed
as one part and the wet weight was recorded. The SV was then drained of fluid and the
weight recorded as weight without fluid (SVd). Seminal fluid weight was recorded as the
difference between the wet weight and SVd. The testes, as well as ventral and lateral lobes
of the prostate (VP and LP, respectively) were removed and weighed. The dorsal prostate
was not removed. Macroscopically visible masses presenting as light orange to dark red
nodular lipomatous discolorations (presumptive inflammation +/− hemorrhage) measuring
about 2-30 mm in the inguinal region and macroscopic pale prostatic foci (presumptive
inflammatory cell infiltrates present on only the lateral and ventral lobes) measuring 1-2 mm
were observed and recorded by the pathologist at necropsy and were collected for
microscopic evaluation. Tissues for histology were fixed in neutral buffered formalin (10%).
2.6 Radioimmunoassays
Radioimmunoassays utilizing rat specific antibodies were performed as previously described
[6] to measure prolactin (sPRL), thyroid-stimulating hormone (sTSH), luteinizing hormone
(sLH) in serum, and prolactin (pPRL) and thyroid-stimulating hormone (pTSH) in pituitary
tissue. Serum testosterone (sT) concentrations were determined using Coat-A-Count®
antibody-coated tube kits from Diagnostic Products Corp. (Los Angeles, CA), as instructed
by the manufacturer. Serum estradiol (sE2) and estrone (sEN) concentrations were
determined using kits from Diagnostic Systems Laboratory, Inc. (Webster, TX), as
instructed by the manufacturer. All assays were performed in duplicate, using 2-3 quality
control samples dispersed throughout the experimental samples and inter-assay coefficients
of variation for T, PRL, E2, EN, and TSH were 6.3%, 7.0%, 6.0%, 6.3%, and 4.2%,
respectively..
2.7 Histopathology
The fixed VP and LP were processed by routine methods and embedded in a paraffin block.
Each block was then step-sectioned; one 5 μm section was retained every 20-25 sections to
provide five sections of each of the lateral and ventral lobes of the prostate for staining with
hematoxylin and eosin. Each slide was examined microscopically by three pathologists
without knowledge of treatment and because the inflammation involved both the VP and LP,
the lobes were graded as a whole. Severity of inflammation was scored as follows: 1 -
minimal multifocal interstitial infiltration of inflammatory cells involving less than 10% of
the gland, 2 – multifocal to coalescing moderate interstitial inflammation affecting 10-25%
of the gland, with or without focally marked accumulations of perivascular collections of
inflammatory cells or mild fibrosis, 3 – multifocal, marked interstitial inflammation
involving 25-75% of the gland, with or without focally marked accumulations of
perivascular collections of inflammatory cells, moderate fibrosis, or sloughing and necrosis
of the epithelial lining with intraluminal accumulations of neutrophils (micro-abscesses), or
4- diffuse and extensive interstitial inflammation involving > 75% of the gland often with
interstitial fibrosis and occasional microabscesses.
A section of the VP was stained for the presence of proliferating cell nuclear antigen
(PCNA). At 200X magnification, ten random images of the VP were selected from each
animal. It was determined that there was an average of 79.3 countable nuclei present in each
image. Therefore, 800 nuclei per animal were used as the denominator for calculation of the
labeling indices. A nucleus was considered positive if it stained moderately dark brown or
darker. Mitotic figures were also included in the count for the numerator.
Stanko et al. Page 5














Unless otherwise indicated, treated dams were utilized as the unit of measure for endpoints
measured prior to and including PPS. Data were analyzed for effects by analysis of variance
(ANOVA) using the general linear model (GLM) or mixed model in SAS 9.1 (SAS Institute,
Inc., Cary, NC). Replicate (block) effects were assessed for each parameter and no block
effect was found to exist outside of block two PRL data, which is addressed in section 3.4.
Body weight was utilized as a covariate where appropriate. Means were evaluated and
treatment groups were compared to the control group using Dunnett's multiple comparisons
post-hoc test. Treatment groups were evaluated independently of positive controls to
conserve linearity. Prostate pathology incidence and severity scores were analyzed for dose-
dependent associations in a contingency table using Mantel-Haenszel chi-square analysis
and Wilcoxon non-parametric analysis, respectively. All data are reported as means
±standard error and p<0.05 was used to indicate significant differences.
3. Results
3.1 Maternal weight gain
Maternal weight gain of 100 mg ATR dams (21.2 ±7.7 g) during the dosing period was
significantly lower than controls (54.8 ±2.5 g; p<0.05). Unlike the ATR exposure, AMM
treated dams had a mean weight gain that was 4-12% more than vehicle controls, but this
difference was not significant (see also [24]).
3.2 Offspring Body Weights
There were no significant differences in the litter size of treated dams compared to control
dams and fetal (GD20) BW of males in the 8.73 mg AMM treatment group was significantly
greater than that of control males (data is reported in [24]). No statistically significant
differences in body weight were observed between control males and males in any treatment
group during the lactational period (PND4 or PND21; Figure 3). On PND120, male
offspring of the 0.09 mg AMM treatment group (586.7 ±19.0 g; p=0.05) weighed
significantly less than male offspring of the control group (622.1 ±15.5 g); an effect not
present in that treatment group on PND180. On PND180, male offspring in the 0.87 mg
AMM treatment group (739.1 ±13.2 g; p=0.05) and in the 8.73 mg AMM treatment group
(744.1 ±14.6 g; p<0.05) weighed significantly more than controls (681.8 ±21.9 g). Besides
the single exception of the 0.09 mg AMM group on PND120, the male offspring were
similar in weight to controls until PND180, at which time the two highest AMM dose
groups were significantly elevated above control levels.
3.3 Preputial Separation
Preputial separation was significantly delayed in male offspring of the 0.87 mg AMM (42.3
±0.3 d, p<0.05), 8.73 mg AMM (42.3 ±0.3 d, p<0.05) and 100 mg ATR (43.1 ±0.3 d,
p<0.01) treatment groups compared to control males (41.5 ±0.2 d) (Figure 4). Although the
mean day of PPS was the same for all AMM-exposed offspring, the delay in PPS was only
nearly statistically significant in males of the 0.09 mg AMM treatment group (42.3 ±0.4 d,
p=0.06) due to the slight increase in variability of response in that group. Weight at PPS was
significantly greater in males of the 0.87 mg AMM treatment group (240.6 ±3.6 g, p<0.05),
when compared to control males (228.8 ±3.2 g; Fig. 4B), suggesting that decrements in body
weight gain in AMM-exposed males do not account for the slight delay in puberty. In
addition, where PPS had not occurred by PND44 (PPS ≥ 45 days; a day randomly chosen
based on the general window for PPS timing) in only 4.5% of control males, it had yet to
occur by PND44 in nearly 13% or more of males in each of the AMM treatment groups and
28% of males in the ATR treatment group. All animals had achieved PPS by PND51.
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Because previous studies [6,12] implicated altered maternal/pup PRL regulation as a
possible mechanism of action for later life effects (including prostatitis) following ATR
exposure, these studies evaluated that hormone, and others, for persistent effects that may be
treatment related. The mean sPRL of all block two animals was elevated to more than three
times the mean sPRL of block one and three animals, and was evident as a block effect. The
elevated sPRL levels could indicate that these animals experienced environmental stress at
some point just prior to necropsy and, therefore, sPRL data from block two was not
considered in data analysis. Additionally, two control animals and one treated animal from
block one exhibited sPRL levels>20 ng/ml, which was also could be attributed to
unidentified environmental stress. These samples were considered outliers using statistical
methods and were not included in data analysis. Once excluded, there were no further block
effects detected in this study. Based on our results from PND120, only serum T, PRL, E2,
and EN were measured on PND180. The results of hormone analyses for PND120 and
PND180 are shown in Table 2.
On PND120, males of the 100 mg ATR treatment group had significantly higher mean sT
(2.37 ±0.38 ng/ml, p<0.01) and sEN (55.3 ±4.6 pg/ml, p<0.05), compared to controls (1.48
±0.15 ng/ml and 39.4 ±2.9 pg/ml, respectively). Although these were the only significant
differences noted on PND120, all treatment groups exhibited a non-significant trend of
elevated sT, sPRL, sE2, and sEN. Conversely, there was a significant treatment-related
decrease in sT and sE on PND180. The mean sT of 8.73 mg AMM males (1.09 ±0.18 ng/ml,
p<0.05) was significantly lower than controls (2.72 ±0.65 ng/ml) and mean sE2 was
significantly lower (p<0.05-0.01) in all treatment groups compared to controls. Despite these
significant changes in hormones levels, the patterns of which were not consistent over time,
nearly all mean hormone concentrations were within the normal reported ranges for the
respective hormones measured. These data do not support an association between altered
serum or pituitary PRL concentrations and prenatal exposure to ATR or AMM in LE rats.
3.5 Necropsy observations and analyses
Tissue weights at PND120 and PND180 are summarized in Table 1. AP weight on PND120
was significantly greater in 0.87 AMM-exposed (11.72 ± 0.29 mg, p<0.01) and 100 mg
ATR-exposed (11.82 ± 0.49 mg, p<0.01) males, compared to control males (10.11 ± 0.37
mg). Neither mean testes nor mean SV weights were significantly different in exposed males
of any treatment group compared to controls on PND120. The mean VP weight of 8.73 mg
AMM-exposed males (410.5 ± 19.1 mg, p<0.05) was significantly less compared to the
control mean (473.6 ± 19.1 mg), while statistical analysis of a treatment-associated decrease
in VP weight in AMM exposed males on PND 120 resulted in p=0.06. There were no
statistical differences in mean LP weight between any treatment group and controls on either
PND120 or PND180. No significant differences in mean tissue weights of treated males
compared to control males were observed on PND180.
There was a significant dose-dependent increase in the percentage of males exhibiting
lipomatous epididymal fat masses collected at necropsy at both PND120 and PND180
(p<0.05; Figure 5). These masses were followed up with histopathologic evaluation, the
results of which are reported below. There was also a significant increase in the incidence of
pale prostatic foci of discoloration (presumptive inflammatory cell infiltrates) noted in the
exposed males at necropsy at both at 120 and 180 days (p<0.05; Figure 5).
3.6 Histopathology
There was a significant dose-dependent increase in prostate inflammation in AMM-exposed
offspring on PND120 and the severity of prostate inflammation on PND120 was
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significantly greater in male offspring of all AMM exposure groups compared to controls
(p<0.05; Table 3). The inflammation involved both the lateral prostate and ventral prostate,
and was not specific to particular regions of a lobe. Overall, prostate effects included cell
infiltrates that were multifocal to regionally extensive and comprised primarily by mature
lymphocytes with occasional plasma cells, macrophages, mast cells, and neutrophils. The
PND120 prostate effects were typically characterized by multifocal to coalescing moderate
interstitial inflammation affecting 10-25% of the gland, with or without focally marked
accumulations of perivascular collections of inflammatory cells with minimal to moderate
fibrosis (Figure 6). In addition to the significant increase in incidence of prostatitis in the
ATR-exposed males, both the mean overall severity scores and severity scores of affected
males on PND120 were greater in all AMM treatment groups than those of the ATR
exposed group (Table 3). The significance of effect noted in incidence, overall severity
scores, and severity among affected animals in PND 120 males was not continued on
PND180 (Table 4). The effects in exposed animals appeared to dissipate over time while the
control group did not vary between time points.
Although there was a high incidence and degree of inflammation in the prostate, there was
no indication of progression to neoplasia at PND 120 or 180 in tissues of control or AMM or
ATR-exposed males. No significant difference was observed in the percentage of
proliferating epithelial cells in PND120 prostate sections. On PND180, only prostate
sections of the 0.09 mg AMM treatment groups exhibited significantly more labeled
epithelial cells in the prostate than controls (data not shown).
Although gross characterization of the epididymal fat masses suggested a possible
differential diagnosis of lipoma, histological analysis demonstrated multifocal fat necrosis
and infarction of fat lobules with associated chronic histiocytic steatitis and chronic
hemorrhage of epididymal fat (Figure 7). The exact cause is not apparent but considerations
would include vascular compromise, local trauma, or steatitis related to a systemic disease
such as uremia, autoimmunity, or pancreatitis, though no information was available in the
present study to confirm or refute this (data not shown).
4. Discussion
This is, to our knowledge, the first study to report the effects of exposure to a biologically
relevant mixture of ATR and its environmental metabolites on reproductive development in
the male rat. The effective AMM concentrations utilized in this study, administered during a
critical period of male reproductive tract development, are considerably lower than the
current no observed adverse effect level (NOAEL) for ATR derived from previous studies
that focused on male reproductive end points. Our key findings were significant treatment-
related delays in PPS and increased incidence and severity of prostatitis on PND120
following a 5-day in utero exposure to the AMM. The fact that these health effects were
treatment-related suggests that the AMM may be as potent as or more so than ATR alone.
The data reported here are from the male siblings of females studied by Enoch et al. [24]. In
that report, significant treatment-related increases in female offspring BW on PND4 in all
AMM doses tested and on PND60 in 0.87 and 8.73 mg AMM exposed offspring were
described. In the current study, there was no significant increase in male offspring BW on
PND4, PND21, or PND120, but BW was significantly greater than controls in the 0.87 mg
AMM and 8.73 mg AMM treatment groups on PND180. Thus, in contrast to ATR alone,
this low dose AMM not only had no deleterious effect on BW, but BW was in fact elevated
in both male and female offspring at the same doses, though there were variations in the rate
of the response across gender.
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In the present study, there was a significant, albeit marginal, delay in PPS in males of the
two highest AMM treatment groups, and a nearly significant delay (p<0.06) in males of the
lowest AMM treatment group. While the biological significance of a less than one day delay
in PPS is not clear, these data, in accordance with the Tier 1 Screening Battery of the U.S.
EPA Endocrine Disruptor Screening Program Test Guidelines [32], indicate that PPS is
clearly a particularly sensitive endpoint following developmental exposure to ATR and its
metabolites and that an AMM treatment effect does exist at low levels. Further, the
observation of pubertal delays in the absence of any significant reductions in peripubertal
BW are consistent with studies reviewed in Cooper et al. [4] where both male and female
pubertal onset was delayed while BW was increased following early-life exposure to ATR
or its individual metabolites. Data in the present study, Enoch et al. [24], and of those
described in Cooper et al. [4] suggest that significant effects on pubertal timing following
developmental exposures to low levels of ATR, its individual metabolites, or the AMM are
not associated with peripubertal BW effects. To this point, the later life ramifications of
delayed puberty and the mechanism(s) of action driving this response are not known.
In addition to delayed puberty, treatment-dependent alterations in the weights of other
reproductive tissues have been reported in male rats following prenatal [14] and peripubertal
[33] exposure to ATR and following peripubertal exposure to individual ATR metabolites
[23]. However, whereas puberty was mildly delayed by biologically relevant levels of the
metabolite mixture in the present study, there were no persistent effects on reproductive tract
or other tissue weights, a characteristic that has been observed in at least one other study
which utilized similar doses of ATR (0 to 100 mg/kg/d) and a similar dosing period (GD 14-
parturition) [34]. While PPS, normally androgen dependent, was delayed in the Rosenberg
study, there were no concomitant changes in intratesticular testosterone (iT) concentrations.
A similar effect was also observed in the present study in which there were no significant
changes in sT in males of the AMM treatment groups on PND120 and only in males in the
highest AMM treatment group was sT reduced on PND180. Interestingly, in males of the
100 mg ATR treatment group, where PPS was delayed at the p<0.01 level, sT was actually
elevated on PND120. However, in that treatment group, no T-regulated tissue weights were
altered; only mean AP weight was significantly greater than that of controls. Trentacoste et
al. [33] reported decreased SV and VP weights in Sprague-Dawley rats exposed to 100 mg
ATR/kg BW peripubertally, but also reported decreased iT and sT, a correlation not
observed in the present study. These differences may be due entirely to the timing of
exposure, as the animals in the Trentacoste study were dosed peripubertally and not
gestationally, as were those in the present study. While the absence of persistent effects on
male reproductive tract tissue weights in the present study is certainly understandable
considering the lack of changes in circulating hormone concentrations, there does not appear
to be a relationship between AMM or ATR-induced pubertal delays and changes in male
reproductive tract tissue weights or circulating hormone concentrations.
It is well known that hormonal changes can influence prostate development and a number of
studies indicate that PRL in particular stimulates prostatic growth in rats [35-38]. Although
there were significant treatment-related effects on the incidence of prostate inflammation
and severity in the current study, there were no concomitant changes in circulating hormone
concentrations that would suggest a mode of action for prostate effects. In addition to
hormonal changes, timing of exposure can also impart late-life prostate effects and a number
of studies have described a critical window for male reproductive tract development
following exposure to various environmental contaminants [39-42]. The window of
sensitivity for prostate development occurs on GD14-19, when androgen receptors are
activated and the testes begin producing androgens [41,42] and the animals utilized in the
present study were exposed to the AMM on GD15-19. Atrazine has been shown to have an
anti-androgenic effect through suppression of the conversion of testosterone to 5α-
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dihyrdrotestosterone (DHT) in the hypothalamus, anterior pituitary, and prostate [43] and
that 5α-DHT prostate receptors are strongly inhibited in offspring of dams exposed to ATR
and DEA during pregnancy [44]. In addition, Babić-Gojmerac et al. [45] demonstrated that
DEA, a component of the AMM, inhibited 5α-reductase at the same rate as ATR in vivo and
at a greater rate than ATR in vitro. Though DEA is likely less toxic due to rapid metabolism
and biodegradation, the metabolic product, DACT, is also a component of the AMM and has
been to shown have developmental effects similar to that of ATR [22,23]. These
observations suggest that GD15-19 is an effective window for AMM exposure to elicit
prostate effects and that other hormones, in addition to those measured in the present study,
be investigated for a potential role in a mode of action for prostate effects. Furthermore, we
suggest that hormones which may be affecting these developmental outcomes should be
evaluated during earlier stages of life, as persistent effects have been absent in both of our
studies [present, 14].
An elevated incidence of lipomatous nodules was indicated in AMM/ATR-exposed rats.
Similar fat nodules have been commonly observed in dogs, horses, and humans. The pale
prostatic foci observed at necropsy on the outer edges of the tissue indicated focal regions of
inflammation. While there is an evident AMM-related effect on the incidence and severity
of inflammation in the prostate on PND120, this was not the case over time as these effects
had dissipated by PND180. It is possible that the appropriate time point necessary to observe
related changes pertinent to the inflammatory effects was not assessed. In a preliminary
study, PND120 males in the 8.73 mg AMM treatment group, which had the most severe
prostate effects, exhibited the highest concentrations of serum IL-1α and IL-6 (data not
shown), two interleukins known to have roles in the resolution of inflammation [46]. Cowin
et al. [41] also observed increased activation of nuclear factor-kappa B-dependent genes,
including IL-1α and IL-6, in prostates of Sprague-Dawley rats exposed in utero on GD14-19
to vinclozolin. This would suggest that the prostate lesions could have been resolving or
under repair and it is possible that had necropsy been conducted earlier than PND120 in the
present study, the severity might have been greater, a more prominent treatment effect
would have been discerned, and/or exposure-related effects (changes in hormones or tissue
weight) would have been detected. Further, this study has added to the knowledge base the
fact that low dose, biologically relevant exposures to ATR and its metabolites induce
prostate inflammation following early life, acute exposures and this study and others [12,14]
confirm that these lesions show no signs of progression to neoplasm at the time points
evaluated and in a strain of rat that is fairly resistant to tumor formation.
The present study, using the lowest effective concentrations of AMM, suggests that late
prenatal exposure to a mixture of atrazine and its metabolites significantly delays puberty
(albeit modest compared to high dose ATR) and can affect adult prostate incidence and
severity of inflammation in Long-Evans rats. The low doses and short duration of exposure
may be the reason that typical dose-related increases in many of the responses were limited
and these findings may be exacerbated by extended exposure. However, the fact that
statistically significant low-dose responses were evident following prenatal exposure to
metabolites of chlorotriazine herbicides is noteworthy as these low dose effects may stem
from the late prenatal time of exposure, during which growth and development of male
reproductive organs are particularly sensitive to environmental agents. The importance of
these findings on late life health effects is not known, as no report to date has extended past
those reported in Rayner et al. [14] or herein, but evidence in this study supports the notion
that time points earlier than 120d may be more important than those in late life with respect
to a mechanism of AMM effect on male reproductive development. The effects reported
here occurred with no decrease in body weight at puberty, as has been previously reported
for ATR alone [13,14] and puberty was significantly delayed at 0.87 mg AMM which is
lower than the current NOAEL for ATR or DACT (6.25 mg/kg/day total dose [28]).
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Additionally, effects were consistently observed in the AMM treatment groups, where the
highest effective concentration (8.73 mg AMM/kg BW) contains only 1.79 mg ATR/kg BW.
These studies suggest that low dose exposures to the chlorinated metabolites of ATR, as a
mixture, may elicit effects that are relevant to human health, in a manner similar to high
dose ATR exposure in male rats exposed just prior to birth.
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LP lateral prostate
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SEM standard error of the mean
SVd dry seminal vesicle
T testosterone
TSH thyroid stimulating hormone
VP ventral prostate
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Catabolism of atrazine and simazine into primary metabolites and further breakdown
products.
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Experimental design. Dams were gavaged on GD15-19 with AMM, 100 mg ATR/kg body
weight, or vehicle. Body weight was recorded on PND4, 21, at PPS, PND120, and 180.
Preputial separation (PPS) was observed from PND38-51. Necropsy was conducted on
PND120 and PND180.
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Body weight of male offspring exposed to vehicle (control), AMM or positive control (100
ATR) on (A) PND4, (B) PND21, (C) PND120, and (D) PND180. Data are presented as
means ± SE for respective treatment group. * Significantly different from control by
Dunnett's multiple comparison (p<0.05). n > 10 dam/group for PND4 and 21; PND120 n =
10, 12, 13, 14, 8, respectively; PND180 n = 21, 18, 21, 19, 16, respectively.
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(A) Age in days at time of preputial separation. Data are presented as mean ± SE for the
respective treatment group. Pup n = 67, 47, 64, 66, and 40, respectively. * Significantly
different from control by Dunnett's multiple comparison (p<0.05). ** Significantly different
from control by Dunnett's multiple comparison (p<0.01). (B) Body weight at PPS. *
Significantly different from control by Dunnett's multiple comparison (p<0.05).
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Percentage of animals exhibiting abnormal epididymal fat masses and pale prostatic foci at
necropsy on A) PND120 (n = 10, 12, 13, 14, 8, respectively) and B) PND180 (n = 21, 18,
21, 19, 16, respectively). * Significant treatment related effect on the gross observation of
masses and foci at each time point by chi-square analysis (p<0.05).
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Histological sections of lateral prostate, hematoxylin and eosin (HE) stain. Scale bars are
100 μm. A) Unaffected prostate of control male on PND120 (score=0, unaffected). B)
Lateral prostate section of offspring in the 0.09 mg AMM treatment group on PND120 with
severity score=1; minimal multifocal interstitial infiltration of inflammatory cells involving
less than 10% of the gland. C&D) Lateral prostate section of offspring in the 8.73 mg AMM
treatment group on PND120 at low and high magnification, respectively, demonstrating
prostatitis with predominant lymphoid infiltrate (severity score=4; diffuse and extensive
interstitial inflammation involving > 75% of the gland often with interstitial fibrosis).
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Histological section of abnormal epididymal fat mass, H&E stained. Scale bars are 100 μm.
A) Low magnification of mass from 8.73mg AMM treatment group. B) High magnification
of (A). Larger arrow indicates necrotic fat, smaller arrow indicates hemorrhage, and
arrowhead indicates histiocytic steatitis.
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Table 3




Control 12/25 (48%) 0.6 ± 0.2 (1.3 ± 0.2)
0.09 AMM 14/21 (67%) 1.4 ± 0.3 (2.1 ± 0.2)**
0.87 AMM 19/25 (76%) 1.4 ± 0.2 (1.8 ± 0.2)**
8.73 AMM 20/25 (80%) 1.5 ± 0.2 (1.9 ± 0.2)**
100 ATR 17/21 (81%) 1.2 ± 0.2 (1.5 ± 0.2)
Note: PND, postnatal day; AMM, atrazine metabolite mixture; ATR, atrazine. Data represent incidence of alteration in the ventral and lateral
prostate combined, followed by the mean severity score ± SE (mean severity score ± SE for the subset of animals with the alteration).
*
Significant dose-dependent increase in the incidence of inflammation by Mantel-Haenszel chi-square analysis (p<0.05).
**
Significantly higher severity of inflammation compared to controls by ANOVA (p<0.05).
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Table 4




Control 11/20 (55%) 0.7 ± 0.2 (1.3 ± 0.1)
0.09 AMM 4/18 (22%) 0.4 ± 0.2 (2.0 ± 0.4)
0.87 AMM 13/21 (62%) 0.8 ± 0.2 (1.2 ± 0.1)
8.73 AMM 11/19 (58%) 0.9 ± 0.2 (1.6 ± 0.2)
100 ATR 6/16 (34%) 0.7 ± 0.3 (1.8 ± 0.3)
Note: PND, postnatal day; AMM, atrazine metabolite mixture; ATR, atrazine. Data represent incidence of alteration in the ventral and lateral
prostate combined, followed by the mean severity score ± SE (mean severity score ± SE for the subset of animals with the alteration).
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